In cells resistant to combined BRAF and MEK inhibition, PAKs modulate the phosphorylation of JNK and β-catenin and the activation of the mTOR pathway, supporting that PAK signaling is responsible for acquired resistance to MAPK inhibitors in BRAF-mutant melanoma (39). Here, MAP2K7 is linked to melanoma.